Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Bristol-Myers Squibb (BMY) stock shows potential for growth with recent FDA approval and strong oncology portfolio, but faces ...

The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

Prime Medicine, Inc. has recently entered into a strategic research collaboration and license agreement with Bristol Myers Squibb (BMS) to develop and commercialize multiple prime edited ex vivo ...

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), tracking the healthcare companies under S&P 500, rose 6.27% in ...

We’re only a few months a way from the end of the year, but pharma companies still have a steady stream of clinical trial ...

You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.